Cite
Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial.
MLA
Petersen, Jeff Zarp, et al. “Effects of Recombinant Human Erythropoietin on Cognition and Neural Activity in Remitted Patients with Mood Disorders and First-Degree Relatives of Patients with Psychiatric Disorders: A Study Protocol for a Randomized Controlled Trial.” Trials, vol. 19, no. 1, Nov. 2018, p. N.PAG. EBSCOhost, https://doi.org/10.1186/s13063-018-2995-7.
APA
Petersen, J. Z., Schmidt, L. S., Vinberg, M., Jørgensen, M. B., Hageman, I., Ehrenreich, H., Knudsen, G. M., Kessing, L. V., & Miskowiak, K. W. (2018). Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial. Trials, 19(1), N.PAG. https://doi.org/10.1186/s13063-018-2995-7
Chicago
Petersen, Jeff Zarp, Lejla Sjanic Schmidt, Maj Vinberg, Martin Balslev Jørgensen, Ida Hageman, Hannelore Ehrenreich, Gitte Moos Knudsen, Lars Vedel Kessing, and Kamilla Woznica Miskowiak. 2018. “Effects of Recombinant Human Erythropoietin on Cognition and Neural Activity in Remitted Patients with Mood Disorders and First-Degree Relatives of Patients with Psychiatric Disorders: A Study Protocol for a Randomized Controlled Trial.” Trials 19 (1): N.PAG. doi:10.1186/s13063-018-2995-7.